{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:05:06Z","timestamp":1771020306721,"version":"3.50.1"},"reference-count":47,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s462872","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:20:36Z","timestamp":1716556836000},"page":"437-445","source":"Crossref","is-referenced-by-count":4,"title":["Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada"],"prefix":"10.2147","volume":"Volume 16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-4890","authenticated-orcid":true,"given":"Nigel","family":"Rawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,5]]},"reference":[{"key":"ref1","volume-title":"A Short Primer on Why Cancer Still Sucks","year":"2022"},{"key":"ref2","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2021. Toronto: Canadian Cancer Society; 2021. Available from: www.cancer.ca\/Canadian-Cancer-Statistics-2021-EN. Accessed April 20, 2024."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/cam4.1454","volume":"7","author":"Stewart","year":"2018","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1634\/theoncologist.2019-0314","volume":"25","author":"Gotfrit","year":"2020","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1007\/s00520-020-05907-x","volume":"29","author":"Longo","year":"2021","journal-title":"Support Care Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40487-022-00187-3","volume":"10","author":"Vanderpuye-Orgle","year":"2022","journal-title":"Oncol Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/curroncol29040223","volume":"29","author":"Garaszczuk","year":"2022","journal-title":"Curr Oncol"},{"key":"ref8","first-page":"155","volume":"103","author":"Powers Smith","year":"2021","journal-title":"Am Fam Phys"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.3390\/cancers13184705","volume":"13","author":"Rodak","year":"2021","journal-title":"Cancers"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e1945","DOI":"10.1002\/cnr2.1945","volume":"7","author":"Rismanbaf","year":"2023","journal-title":"Cancer Rep"},{"key":"ref11","unstructured":"Pigott E, Binder L. Getting better, faster: the case for optimizing access to precision medicines in the wake of the revolution in cancer care. Collective Oncology Network for Exchange, Cancer Care Innovation. Treatment Access & Education; 2023. Available from: https:\/\/conected.ca\/wp-content\/uploads\/Getting-Better-Faster-July-5-2023-FINAL-For-Sharing-1.pdf. Accessed April 20, 2024."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.3390\/curroncol29030166","volume":"29","author":"MacPhail","year":"2022","journal-title":"Curr Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fphar.2019.00196","volume":"10","author":"Salek","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/curroncol29020041","volume":"29","author":"Gotfrit","year":"2022","journal-title":"Curr Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/curroncol29030127","volume":"29","author":"Binder","year":"2022","journal-title":"Curr Oncol"},{"key":"ref16","unstructured":"Rawson N, Adams J Waiting for new drugs for rare disorders in Canada. Ottawa: Macdonald-Laurier Institute; 2023. Available from: https:\/\/macdonaldlaurier.ca\/wp-content\/uploads\/2023\/09\/20230822_Rare-drugs-RawsonAdams-COMMENTARY-v1-1.pdf. Accessed April 20, 2024."},{"key":"ref17","unstructured":"Access and time to patient prescription drugs in Canada. Ottawa: Conference Board of Canada; 2024. Available from: https:\/\/www.conferenceboard.ca\/product\/access-and-time-to-patient-jan2024\/. Accessed April 20, 2024."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Glennie J, Gesy K, Nguyen Y Canadian public payer best practices for providing timely patient access to cancer therapies. Can Health Policy; 2023. Available from: https:\/\/doi.org\/10.54194\/VIEL2883. Accessed April 20, 2024.","DOI":"10.54194\/VIEL2883"},{"key":"ref19","unstructured":"Who we are. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024. Available from: https:\/\/www.cadth.ca\/who-we-are. Accessed April 20, 2024."},{"key":"ref20","unstructured":"MacPhail E, Shea B An inside look at the early history of the CADTH Common Drug Review in Canada. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/early_history_of_CDR.pdf. Accessed April 20, 2024."},{"key":"ref21","unstructured":"Why CADTH. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: https:\/\/www.cadth.ca\/why-cadth. Accessed April 20, 2024."},{"key":"ref22","unstructured":"Financial statements of the Canadian Agency for Drugs and Technologies in Health: year ended March 31, 2023. Ottawa: KPMG; 2023. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/Annual_Report\/2023\/2023-03-31%20CADTH%20wFS%20ENG%20-%20signed.pdf. Accessed April 20, 2024."},{"key":"ref23","unstructured":"About pCPA. Toronto: pan-Canadian Pharmaceutical Alliance; 2024. Available from: https:\/\/www.pcpacanada.ca\/about. Accessed April 20, 2024."},{"key":"ref24","unstructured":"pCPA Corporation: inaugural report. Toronto: pan-Canadian Pharmaceutical Alliance; 2023. Available from: https:\/\/www.pcpacanada.ca\/sites\/default\/files\/2023-10\/InauguralReport_pCPA_EN_web.pdf. Accessed April 20, 2024."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e008100","DOI":"10.1136\/bmjopen-2015-008100","volume":"5","author":"Milliken","year":"2015","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3389\/fphar.2018.01578","volume":"9","author":"Salek","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref27","unstructured":"Procedures for CADTH reimbursement reviews. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/Drug_Review_Process\/CADTH%20Drug%20Reimbursement%20Review%20Procedures.pdf. Accessed April 20, 2024."},{"key":"ref28","unstructured":"pCPA brand process guidelines. Toronto: pan-Canadian Pharmaceutical Alliance; 2023. Available from: https:\/\/www.pcpacanada.ca\/sites\/default\/files\/eng\/pCPA_Brand_Process_Guidelines.pdf. Accessed April 20, 2024."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/curroncol31030110","volume":"31","author":"Sehdev","year":"2024","journal-title":"Curr Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/curroncol31040136","volume":"31","author":"Sehdev","year":"2024","journal-title":"Curr Oncol"},{"key":"ref31","unstructured":"About us. Toronto: CanCertainty Coalition; 2024. Available from: https:\/\/www.cancertaintyforall.ca\/about_us. Accessed April 20, 2024."},{"key":"ref32","unstructured":"Reimbursement review reports. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2024. Available from: https:\/\/www.cadth.ca\/reimbursement-review-reports. Accessed April 20, 2024."},{"key":"ref33","unstructured":"Brand name drug negotiations status. Toronto: pan-Canadian Pharmaceutical Alliance; 2024. Available from: https:\/\/www.pcpacanada.ca\/negotiations. Accessed April 20, 2024."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e230178","DOI":"10.57264\/cer-2023-0178","volume":"13","author":"Balijepalli","year":"2024","journal-title":"J Comp Eff Res"},{"key":"ref35","unstructured":"Performance standards for the fees in respect of drugs and medical devices order. Ottawa: Government of Canada; 2024. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/drugs-health-products\/performance-fees-drugs-medical-devices.html. Accessed April 20, 2024."},{"key":"ref36","unstructured":"Fee schedule for CADTH pharmaceutical reviews. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2023. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/Drug_Review_Process\/CADTH_Application_Fees_pharm.pdf. Accessed April 20, 2024."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/CEOR.S144695","volume":"9","author":"Rawson","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref38","unstructured":"Lin JK, Barnes JI, Doshi JA, et al. Arriving at a fair price in the Medicare drug price negotiation program: considerations from other countries. Health Aff Forefront; 2023. Available from: https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20231127.569606. Accessed April 20, 2024."},{"key":"ref39","unstructured":"Rawson NSB, Adams J. Why US Medicare drug price assessments and negotiations should not use Canada as a model. 2024. Available from: https:\/\/www.healthaffairs.org\/content\/forefront\/why-us-medicare-drug-price-assessments-and-negotiations-should-not-use-canada-model. Accessed 20 April 2024."},{"key":"ref40","unstructured":"Stories from the frontlines of the fight for innovative therapies. Toronto: Maclean\u2019s; 2023. Available from: https:\/\/macleans.ca\/longforms\/the-fight-for-access-to-innovative-therapies\/. Accessed April 20, 2024."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.3390\/curroncol29100555","volume":"29","author":"Tam","year":"2022","journal-title":"Curr Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.3747\/co.27.6489","volume":"27","author":"Li","year":"2020","journal-title":"Curr Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.3390\/curroncol28060392","volume":"28","author":"Dai","year":"2021","journal-title":"Curr Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13023-022-02390-x","volume":"17","author":"Rawson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jval.2023.02.013","volume":"26","author":"Fontrier","year":"2023","journal-title":"Value Health"},{"key":"ref46","unstructured":"Bellehumeur C Increasing access to innovative medicines: pre-budget consultations in advance of the 2023 budget. Ottawa: Innovative Medicines Canada; 2022. Available from: https:\/\/innovativemedicines.ca\/wp-content\/uploads\/2022\/10\/20221007_FINAL_PreBudget_Consultation-1.pdf. Accessed April 20, 2024."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1200\/JOP.2011.000278","volume":"8","author":"Berry","year":"2012","journal-title":"J Oncol Pract"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=99408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=99408","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:20:53Z","timestamp":1716556853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/timeliness-of-health-technology-assessments-and-price-negotiations-for-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":47,"URL":"https:\/\/doi.org\/10.2147\/ceor.s462872","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}